Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2016 2
2017 1
2018 2
2020 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Soyka M, Müller CA. Soyka M, et al. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24. Expert Opin Pharmacother. 2017. PMID: 28658981 Review.
Clinical implications, benefits and risks of treatment are discussed. Expert opinion: Acamprosate, naltrexone, nalmefene and disulfiram are the only approved 'alcohol-specific' drugs. Acamprosate and naltrexone have been evaluated in numerous clinical trials and rep …
Clinical implications, benefits and risks of treatment are discussed. Expert opinion: Acamprosate, naltrexone, nalmefene and disulfir …
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, Sinha S. Fairbanks J, et al. Mayo Clin Proc. 2020 Sep;95(9):1964-1977. doi: 10.1016/j.mayocp.2020.01.030. Epub 2020 May 20. Mayo Clin Proc. 2020. PMID: 32446635 Review.
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of al …
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, nal …
Medical treatment of alcohol dependence: a systematic review.
Miller PM, Book SW, Stewart SH. Miller PM, et al. Int J Psychiatry Med. 2011;42(3):227-66. doi: 10.2190/PM.42.3.b. Int J Psychiatry Med. 2011. PMID: 22439295 Free PMC article.
The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g., 26.2% more days abstinent than placebo in a recent study) is positive but modest. Acamprosate shows modest efficacy with recently a …
The evidence base for oral naltrexone (6% more days abstinent than placebo in the largest study) and topiramate (prescribed off-label) (e.g. …
Pharmacologic interventions for alcohol use disorder.
Menge J, Evitt B. Menge J, et al. JAAPA. 2025 Jun 1;38(6):e2-e6. doi: 10.1097/01.JAA.0000000000000106. Epub 2025 May 27. JAAPA. 2025. PMID: 40421949 Review.
Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD by the FDA. ...
Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD …
Off-label use of baclofen for alcohol use disorders in India: no ethics without science.
Braillon A, Naudet F. Braillon A, et al. Indian J Med Ethics. 2025 Oct-Dec;X(4):311-312. doi: 10.20529/IJME.2025.044. Indian J Med Ethics. 2025. PMID: 41195930 Free article.
Off-label use of baclofen is the preferred pharmacotherapy for alcohol use disorders in India, despite its negative benefit/harm ratio, and the fact that acamprosate or naltrexone have long been established as robustly evidence-based medicines. ...
Off-label use of baclofen is the preferred pharmacotherapy for alcohol use disorders in India, despite its negative benefit/harm ratio, and …
Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Litten RZ, et al. Subst Abus. 2016 Apr-Jun;37(2):286-98. doi: 10.1080/08897077.2015.1133472. Subst Abus. 2016. PMID: 26928397 Review.
To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a n …
To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, …
Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies.
Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Rolland B, et al. CNS Neurosci Ther. 2016 Jan;22(1):25-37. doi: 10.1111/cns.12489. CNS Neurosci Ther. 2016. PMID: 26768685 Free PMC article.
The dosing and duration of thiamine (vitamin B1) during detoxification should be adapted to nutritional status (EC). For relapse prevention, acamprosate and naltrexone are recommended as first-line medications (grade A). Disulfiram can be proposed as second-line option in …
The dosing and duration of thiamine (vitamin B1) during detoxification should be adapted to nutritional status (EC). For relapse prevention, …
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Chaignot C, et al. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239-1248. doi: 10.1002/pds.4635. Epub 2018 Sep 25. Pharmacoepidemiol Drug Saf. 2018. PMID: 30251424 Free PMC article.
This study was designed to evaluate the safety of this off-label use compared to the main approved drugs for AUD (acamprosate, naltrexone, nalmefene). METHODS: This cohort study from the French Health Insurance claims database included patients, aged 18 to 70 years, with n …
This study was designed to evaluate the safety of this off-label use compared to the main approved drugs for AUD (acamprosate, naltre …
Pharmacological treatment of alcohol use disorder. Scientific evidence.
Attilia F, Perciballi R, Rotondo C, Capriglione I, Iannuzzi S, Attilia ML, Vitali M, Alessandrini G, Scamporrino MCM, Fiore M, Ceccanti M; Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip. Attilia F, et al. Riv Psichiatr. 2018 May-Jun;53(3):123-127. doi: 10.1708/2925.29414. Riv Psichiatr. 2018. PMID: 29912214
While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. ...
While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, nalt …
Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.
Del Re AC, Gordon AJ, Lembke A, Harris AH. Del Re AC, et al. Addict Sci Clin Pract. 2013 Jul 8;8(1):12. doi: 10.1186/1940-0640-8-12. Addict Sci Clin Pract. 2013. PMID: 23835352 Free PMC article.
BACKGROUND: As a quality improvement metric, the US Veterans Health Administration (VHA) monitors the proportion of patients with alcohol use disorders (AUD) who receive FDA approved medications for alcohol dependence (naltrexone, acamprosate, and disulfiram). Evidence sup …
BACKGROUND: As a quality improvement metric, the US Veterans Health Administration (VHA) monitors the proportion of patients with alcohol us …